Emicizumab for non-severe haemophilia A
- PMID: 36716762
- DOI: 10.1016/S2352-3026(23)00033-9
Emicizumab for non-severe haemophilia A
Conflict of interest statement
I am the project lead for the European Haemophilia Safety Surveillance (EUHASS). This is a not-for-profit project supported by 12 pharmaceutical companies, including Roche. The contracting is done by my employer.
Comment on
-
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.Lancet Haematol. 2023 Mar;10(3):e168-e177. doi: 10.1016/S2352-3026(22)00377-5. Epub 2023 Jan 27. Lancet Haematol. 2023. PMID: 36716761 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical